Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)26.37
  • Today's Change-0.35 / -1.31%
  • Shares traded1.38m
  • 1 Year change-7.15%
  • Beta0.4961
Data delayed at least 15 minutes, as of Nov 12 2024 23:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7516011,865
Total Receivables, Net768739693
Total Inventory1,1411,1501,020
Prepaid expenses173230265
Other current assets, total--016
Total current assets2,8332,7203,860
Property, plant & equipment, net1,1141,1651,059
Goodwill, net3,5293,4902,999
Intangibles, net2,9863,2892,151
Long term investments606366
Note receivable - long term------
Other long term assets261282283
Total assets10,80911,01710,426
LIABILITIES
Accounts payable478537411
Accrued expenses626526524
Notes payable/short-term debt000
Current portion long-term debt/capital leases44136604
Other current liabilities, total421449
Total current liabilities1,5861,1141,588
Total long term debt3,6334,0702,917
Total debt4,0734,1073,521
Deferred income tax262368239
Minority interest------
Other liabilities, total560623530
Total liabilities6,0416,1755,274
SHAREHOLDERS EQUITY
Common stock6,8386,9377,043
Additional paid-in capital------
Retained earnings (accumulated deficit)(2080)(2068)(1927)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total11(27)36
Total equity4,7684,8425,152
Total liabilities & shareholders' equity10,80911,01710,426
Total common shares outstanding136135134
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.